Dr. Glass’ strategic oversight and vision have helped n-Lorem to meet the expanding demand for personalized experimental ASO treatments for nano-rare patients
SAN DIEGO, Calif., September 15, 2022, (Business Wire) — n-Lorem, a nonprofit foundation, today announced that Sarah Glass, Ph.D. has been promoted to Chief Operating Officer (COO). In this role, Dr. Glass will lead the day-to-day operations of n-Lorem and continue to implement strategic initiatives that ensure n-Lorem is positioned to meet the current and projected demand for personalized ASOs for nano-rare patients. n-Lorem’s mission is to discover, develop and provide individualized experimental antisense oligonucleotide (ASO) medicines for nano-rare patients (1 to 30 patients with the same mutation worldwide) for free, for life.
“It is with great pleasure and on behalf of the Board of Directors, that I announce promotion of Sarah Glass, Ph.D. to Chief Operating Officer. Sarah has been with n-Lorem a year and in that time has made a profound impact on all facets of our activities,” said Stanley T. Crooke, M.D., Ph.D., Founder, CEO and Chairman of n-Lorem Foundation. “In Sarah’s new role, she will be responsible very broadly to help lead all activities in the Foundation. Please join me in congratulating Sarah for this richly deserved promotion.”
“Like Stan and the rest of the team, n-Lorem is much more than a career for me. n-Lorem represents a unique intersection of personal and professional passions. I view my training in genetics, experience in drug development and clinical research, and personal drive to help nano-rare patients as a privilege and an obligation,” said Sarah Glass, Ph.D., Chief Operating Officer of n-Lorem Foundation. “At n-Lorem, I am able to develop and implement strategic business development initiatives, to lead and grow the organization to meet the enhanced demand from nano-rare patients, and to bring personalized medicines to patients who need them the most.”
“We now have more than 70 patients accepted into n-Lorem, which represents tremendous growth in all areas of our foundation. In order to meet our demand today and plan for even more growth in the future, we have established a senior leadership team, led by myself and Sarah, that is truly outstanding, cohesive, committed and intensely demanding of ourselves and others,” concluded Dr. Crooke.
Dr. Glass had served as n-Lorem’s Chief Development Officer since August 2021. She has over 20 years of experience in clinical development and research across academia, pharmaceutical companies, and CROs. Dr. Glass brings significant strengths and experience as an accomplished research geneticist, rare disease drug developer, and clinical trialist. Prior to joining n-Lorem, she was the Global Head of Rare Diseases at Parexel.
In addition to serving as n-Lorem’s Chief Operating Officer, Dr. Glass is a rare disease patient advocate and volunteers as chair of the DYRK1A Medical and Scientific advisory board, an organization that holds extreme value to Dr. Glass as it seeks to discover treatment for the same ultra-rare neurodevelopmental disease that her son was diagnosed with in October 2020.
- Subscribe to n-Lorem’s Patient Empowerment Program, a podcast series for nano-rare patients
- Watch: n-Lorem Foundation: Offering Hope and Help to Nano-rare Patients
- Watch: n-Lorem Foundation Delivers Hope and Treatment for Patient with Nano-Rare Disease
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem has assisted in the development and treatment of 14 nano-rare patients and received over 100 applications for treatment with more than 40 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube.
Amy Williford, Ph.D.
Director of Communications